LSL Pharma Group Inc.
LSL.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.85M | 2.94M | 3.06M | 3.09M | 2.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.85M | 2.94M | 3.06M | 3.09M | 2.54M |
| Cost of Revenue | 2.80M | 2.06M | 1.94M | 2.24M | 2.47M |
| Gross Profit | 1.05M | 875.40K | 1.12M | 850.00K | 73.50K |
| SG&A Expenses | 970.10K | 786.70K | 1.22M | 717.20K | 747.50K |
| Depreciation & Amortization | -72.90K | 25.70K | -- | -- | -74.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.69M | 2.88M | 3.17M | 2.96M | 3.14M |
| Operating Income | 154.30K | 63.10K | -103.80K | 132.80K | -599.80K |
| Income Before Tax | 3.25M | -283.00K | -377.10K | -207.70K | -933.50K |
| Income Tax Expenses | 35.70K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.21M | -283.00K | -377.10K | -207.70K | -933.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.21M | -283.00K | -377.10K | -207.70K | -933.50K |
| EBIT | 154.30K | 63.10K | -103.80K | 132.80K | -599.80K |
| EBITDA | 343.60K | 322.60K | 149.10K | 380.50K | -585.80K |
| EPS Basic | 0.03 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.03 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 115.93M | 115.08M | 105.77M | 84.58M | 82.43M |
| Average Diluted Shares Outstanding | 115.93M | 115.28M | 105.89M | 84.58M | 82.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |